“The lawsuit claims the drugmaker’s scheme involved publishing misleading articles falsely stating that Tamiflu reduces complications, severity, hospitalizations, mortality and transmission of influenza.
The company then used those articles to aggressively market the drug to the government for pandemic use. Relying on the supposed truthfulness of Roche’s claims, federal and state governments spent about $1.5 billion to stockpile Tamiflu to combat influenza pandemics.”
It wasn’t until repeated requests from The BMJ were honored that data from unpublished trials were released to researchers, revealing the true extent of Tamiflu’s effectiveness — or lack thereof.
In the BMJ review of Tamiflu it’s found that Tamiflu shortened the duration of flu symptoms by less than a day, specifically, by just 16.8 hours, and did not affect the number of hospitalizations. In exchange for this very modest benefit, Tamiflu caused nausea and vomiting and increased the risk of headaches and renal and psychiatric syndromes.
Serious side effects include convulsions, delirium or delusions and suicidal behavior. Japan banned the use of Tamiflu in children and teens in 2007, after cases of teenagers trying to jump from apartment building windows while taking the drug.
Read the full article: articles.mercola.com/sites/articles/archive/2020/01/28/tamiflu-fraud-stole-billions.aspx
Disclaimer: This content does not necessarily represent the views of IWB.